EraCal Therapeutics Ltd.
The biotech-company EraCal Therapeutics Ltd. is a spin-off from the University of Zurich and Harvard University. The company is privately held by a biotech-specialized investor base.
Board of Directors
A. Kessler Ph.D.
Chairman
Ann Kessler held various senior research positions at Roche for over 26 years. She launched the obesity research program, led its clinical development, and brought orlistat (Alli, Xenical) to the market.
B. Ernst Ph.D.
Board Member
Bettina Ernst is a biotech entrepreneur and investor. She serves the Swiss Biotech community in various roles thanks to her deep experience in medical research in the US and Europe.
P. Pfirter MLaw, LL.M.
Board Member
Pauline Pfirter is a lawyer at a leading Swiss law firm, focusing in her legal practice on advising start-ups on any matters of Swiss corporate law, with special focus on biotech start-ups.
Scientific Advisory Board
H. Böttcher Ph.D.
Henning Böttcher is the former head of medicinal chemistry at Merck KGaA.
Prof. F. Engert
Florian Engert is a neuroscience expert and tenured professor at Harvard University.
G. Meyer Ph.D.
Gerd Meyer is Head of Plexus Ventures CH, a leading global development & licensing firm.
Prof. T. A. Lutz
Thomas A. Lutz is an obesity and diabetes expert and tenured professor at the University of Zurich.
T. Weller Ph.D.
Thomas Weller is the former head of medicinal chemistry at Idorsia/Actelion.